
Pro-Dex, Inc. (NASDAQ:PDEX – Free Report) – Equities researchers at Ascendiant Capital Markets increased their Q2 2027 earnings per share (EPS) estimates for shares of Pro-Dex in a report released on Sunday, November 15th. Ascendiant Capital Markets analyst E. Woo now expects that the medical instruments supplier will post earnings per share of $0.73 for the quarter, up from their prior forecast of $0.72. Ascendiant Capital Markets has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Pro-Dex’s current full-year earnings is $3.09 per share. Ascendiant Capital Markets also issued estimates for Pro-Dex’s FY2027 earnings at $3.32 EPS, Q1 2028 earnings at $0.78 EPS, Q2 2028 earnings at $0.82 EPS, Q3 2028 earnings at $0.90 EPS, Q4 2028 earnings at $0.96 EPS and FY2028 earnings at $3.47 EPS.
Pro-Dex (NASDAQ:PDEX – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pro-Dex had a return on equity of 26.18% and a net margin of 15.12%. The company had revenue of $20.56 million during the quarter, compared to analysts’ expectations of $20.40 million.
Other research analysts have also recently issued reports about the company. Zacks Research cut Pro-Dex from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 9th. Weiss Ratings raised Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, November 10th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $80.00.
Read Our Latest Research Report on PDEX
Pro-Dex Stock Down 0.7%
Pro-Dex stock opened at $63.49 on Friday. The business’s 50-day simple moving average is $64.91 and its two-hundred day simple moving average is $58.15. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.49 and a current ratio of 4.19. The company has a market cap of $203.17 million, a PE ratio of 17.52 and a beta of 0.12. Pro-Dex has a fifty-two week low of $29.29 and a fifty-two week high of $77.00.
Hedge Funds Weigh In On Pro-Dex
A number of institutional investors have recently modified their holdings of PDEX. Goldman Sachs Group Inc. raised its stake in shares of Pro-Dex by 6.6% during the 3rd quarter. Goldman Sachs Group Inc. now owns 19,945 shares of the medical instruments supplier’s stock valued at $1,376,000 after buying an additional 1,234 shares during the last quarter. First Trust Advisors LP boosted its stake in shares of Pro-Dex by 26.2% in the third quarter. First Trust Advisors LP now owns 7,487 shares of the medical instruments supplier’s stock worth $517,000 after buying an additional 1,553 shares during the last quarter. Punch & Associates Investment Management Inc. boosted its stake in shares of Pro-Dex by 2.9% in the first quarter. Punch & Associates Investment Management Inc. now owns 61,735 shares of the medical instruments supplier’s stock worth $3,032,000 after buying an additional 1,735 shares during the last quarter. Ritholtz Wealth Management boosted its stake in shares of Pro-Dex by 57.7% in the third quarter. Ritholtz Wealth Management now owns 7,288 shares of the medical instruments supplier’s stock worth $503,000 after buying an additional 2,668 shares during the last quarter. Finally, James Investment Research Inc. purchased a new stake in shares of Pro-Dex in the third quarter worth about $207,000. Hedge funds and other institutional investors own 15.28% of the company’s stock.
Insiders Place Their Bets
In related news, CEO Kirk Richard Lee Van, Jr. sold 765 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $59.36, for a total transaction of $45,410.40. Following the completion of the transaction, the chief executive officer owned 79,228 shares of the company’s stock, valued at $4,702,974.08. This trade represents a 0.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Alisha Charlton sold 2,300 shares of the business’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $61.30, for a total transaction of $140,990.00. Following the transaction, the chief financial officer owned 21,870 shares of the company’s stock, valued at $1,340,631. This represents a 9.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 22,300 shares of company stock worth $1,351,657 in the last quarter. Company insiders own 48.00% of the company’s stock.
About Pro-Dex
Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments and related accessories, with a focus on devices used in orthopedic procedures. Its products include surgical handpieces and drivers, along with the components and systems that support their operation. The company also provides engineering, product development and manufacturing services to medical device companies. Its work can span the product lifecycle, from design and prototyping to production and servicing. Founded in 1978, Pro-Dex is headquartered in Irvine, California, and serves customers in the United States and international markets.
Featured Stories
- Five stocks we like better than Pro-Dex
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.
